Key Points
- COO David Novack sold 114,000 shares on January 15 at an average price of $15.64 for a total of $1,782,960, cutting his stake by 64.28% to 63,344 shares, per an SEC Form 4 filing.
- Shares trade around $15.68 near a 52-week high of $15.73 with a market cap of $1.84 billion; analysts are mixed and the consensus rating is "Hold" with an average target price of $24.33.
- Dynavax recently beat quarterly EPS and revenue estimates but reported a negative net margin (-13.13%), and institutional investors own about 96.96% of the company after several funds materially increased their positions.
Dynavax Technologies Corporation (NASDAQ:DVAX - Get Free Report) COO David Novack sold 114,000 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $15.64, for a total value of $1,782,960.00. Following the completion of the transaction, the chief operating officer directly owned 63,344 shares in the company, valued at approximately $990,700.16. This represents a 64.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Dynavax Technologies Trading Up 0.3%
Shares of NASDAQ:DVAX opened at $15.68 on Wednesday. The stock's 50-day simple moving average is $12.82 and its two-hundred day simple moving average is $11.23. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -42.38 and a beta of 0.89. Dynavax Technologies Corporation has a 52-week low of $9.20 and a 52-week high of $15.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.14 by $0.07. The firm had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. Analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. Marshall Wace LLP lifted its stake in Dynavax Technologies by 107.2% in the 2nd quarter. Marshall Wace LLP now owns 1,814,934 shares of the biopharmaceutical company's stock worth $18,004,000 after purchasing an additional 939,076 shares in the last quarter. Qube Research & Technologies Ltd grew its position in shares of Dynavax Technologies by 163.0% during the third quarter. Qube Research & Technologies Ltd now owns 754,041 shares of the biopharmaceutical company's stock valued at $7,488,000 after purchasing an additional 467,369 shares in the last quarter. Man Group plc increased its holdings in shares of Dynavax Technologies by 925.5% in the second quarter. Man Group plc now owns 447,847 shares of the biopharmaceutical company's stock worth $4,443,000 after purchasing an additional 404,175 shares during the last quarter. Pacer Advisors Inc. lifted its position in shares of Dynavax Technologies by 3,639.9% in the third quarter. Pacer Advisors Inc. now owns 322,119 shares of the biopharmaceutical company's stock worth $3,199,000 after buying an additional 313,506 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its stake in Dynavax Technologies by 222.3% during the second quarter. Squarepoint Ops LLC now owns 435,577 shares of the biopharmaceutical company's stock valued at $4,321,000 after buying an additional 300,421 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company's stock.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the stock. William Blair cut shares of Dynavax Technologies from an "outperform" rating to a "hold" rating in a research note on Wednesday, December 24th. Weiss Ratings reiterated a "sell (d)" rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised Dynavax Technologies from a "buy" rating to a "strong-buy" rating in a report on Saturday, December 27th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $24.33.
Read Our Latest Report on DVAX
Dynavax Technologies Company Profile
(
Get Free Report)
Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.
Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
